Shanghai Fosun Pharmaceutical (Group)600196.SHValuation Analysis

As of Oct 19, 2026, Shanghai Fosun Pharmaceutical (Group) (600196.SH) trades at a P/E of 18.10x, P/B of 1.26x, P/S of 1.50x, and a dividend yield of 1.83%.
Longitudinal percentile comparison: P/E sits at the 5th percentile over the trailing 10Y window (vs. 16th percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S sits at the 7th percentile over the trailing 10Y window (vs. 21st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 18th percentile within its industry and the 21st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.45%, ranking at the 98th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 1.0 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 2.45% total shareholder yield, 1.83% is paid out as dividends and roughly 0.61% is implied to come from buybacks — both channels are meaningfully in play. Shanghai Fosun Pharmaceutical (Group) operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.